As the UMass Chan mourns the recent death of Michael Green, MD, PhD, two faculty have been appointed to fill positions that Dr. Green nobly held. Jonathan M. Gerber, MD, has been appointed director of the UMass Cancer Center, and Michelle A. Kelliher, PhD, will serve as interim chair of the Department of Molecular, Cell & Cancer Biology.

A large, double-blind, randomized controlled trial found that outpatients who received convalescent plasma within nine days of onset of COVID-19 symptoms were significantly less likely to be hospitalized than those who received placebo control plasma.

Jonathan Gerber, MD, discusses a therapy that has been around for at least a century and how it has helped in the COVID-19 pandemic.

Worcester Business Journal readers have chosen the UMass Cancer Walk and Run as the best nonprofit fundraiser event in Central Massachusetts.

Results of a clinical trial led by Jonathan M. Gerber, MD, suggest that early use of convalescent plasma treatment for COVID-19 helps avoid hospitalization.

More than 100 critically ill COVID-19 patients in the UMass Memorial Health Care system have been treated with convalescent plasma through a UMass Medical School clinical trial led by Jonathan M. Gerber, MD.

In an essay originally published by The Conversation, Cancer Center Director Jonathan Gerber, MD, discusses the specifics of recently reported declines in cancer deaths and provides perspective for future continued progress.

Learn about the UMass Cancer Walk and Run and the latest advancements in cancer research in this Voices of UMassMed podcast with Jonathan Gerber, MD.

At an event characterized by a mix of smiles and tears, the race to raise money for the 2019 UMass Cancer Walk and Run officially began on June 3 as more than 100 team leaders, cancer survivors and event sponsors gathered at the Albert Sherman Center.